Despite sinking demand for Comirnaty and Paxlovid, Pfizer's post-COVID future looks bright. In the second quarter, Padcev sales jumped 38% higher year over year to an annualized $2.2 billion. Padcev sales could keep growing by leaps and bounds thanks to recent results from an adjuvant study. In a trial with newly diagnosed patients, Elrexfio shrank tumors for 97% of those treated. With Padcev, Elrexfio, and an experimental obesity treatment still in development, the coming decade could be a great one for patient investors.